Stocktoria
LENZ Therapeutics, Inc. LENZ
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-06-25
LENZ Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $19.1M | $0 | — | — | — |
| R&D expense | $18.7M | $29.8M | $59.5M | $72.8M | $37.9M |
| SG&A expense | $91.1M | $28.8M | $12.9M | — | — |
| Operating income | -$91.1M | -$58.6M | -$72.4M | -$105.6M | -$60.4M |
| Income tax | $502,000 | $1,000 | -$179,000 | $0 | $0 |
| Net income | -$82.1M | -$49.8M | -$70.0M | -$101.1M | -$70.8M |
| EPS (diluted) | $-2.85 | $-2.34 | $-35.71 | $-1.84 | $-2.45 |
| Operating cash flow | -$69.2M | -$59.4M | -$60.4M | -$88.0M | -$52.9M |
| Free cash flow | -$70.0M | -$59.9M | -$60.4M | -$94.6M | -$58.6M |
| Cash & equivalents | $25.2M | $20.2M | $35.1M | $47.7M | $377.0M |
| Inventory | $2.9M | $0 | — | — | — |
| Total assets | $305.9M | $215.3M | $70.4M | $321.9M | $402.0M |
| Total liabilities | $21.5M | $11.2M | $19.7M | $25.6M | $17.9M |
| Shareholders' equity | $284.3M | $204.1M | -$92.7M | -$24.2M | $384.1M |
Source: SEC EDGAR filings · CIK 0001815776 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.